Patients' perspectives on actinic keratosis (AK) treatments may impact on treatment adherence and, therefore, clinical outcomes but are not well characterized. We performed a systematic review to assess patients' perspectives of topical, field-directed AK treatment. A literature search was performed, and 14 studies were identified encompassing 4433 patients. Only three studies focused on face and/or scalp, which are the locations that typically impact patients' quality of life. Four studies were clinical trials. One study utilized a patient-reported outcomes (PRO) instrument specifically developed for AK. In general, treatment adherence and patient satisfaction were better with shorter-duration treatments regimens such as ingenol mebutate gel. Imiquimod improved quality of life in one study but not in another. No data was available on topical piroxicam. The findings underscore the need for effective and well-tolerated, short-duration topical therapies for actinic keratosis.

Patient‐reported outcomes of topical therapies in actinic keratosis : a systematic review / A. Grada, S.R. Feldman, N. Luigi Bragazzi, G. Damiani. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 34:2(2021), pp. e14833.1-e14833.10. [10.1111/dth.14833]

Patient‐reported outcomes of topical therapies in actinic keratosis : a systematic review

G. Damiani
Project Administration
2021

Abstract

Patients' perspectives on actinic keratosis (AK) treatments may impact on treatment adherence and, therefore, clinical outcomes but are not well characterized. We performed a systematic review to assess patients' perspectives of topical, field-directed AK treatment. A literature search was performed, and 14 studies were identified encompassing 4433 patients. Only three studies focused on face and/or scalp, which are the locations that typically impact patients' quality of life. Four studies were clinical trials. One study utilized a patient-reported outcomes (PRO) instrument specifically developed for AK. In general, treatment adherence and patient satisfaction were better with shorter-duration treatments regimens such as ingenol mebutate gel. Imiquimod improved quality of life in one study but not in another. No data was available on topical piroxicam. The findings underscore the need for effective and well-tolerated, short-duration topical therapies for actinic keratosis.
actinic keratosis; adherence; compliance; patient-reported outcomes, topical therapies; safety; systematic review; tolerability
Settore MED/35 - Malattie Cutanee e Veneree
Article (author)
File in questo prodotto:
File Dimensione Formato  
dth.14833-2.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.4 MB
Formato Adobe PDF
1.4 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/831288
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 12
social impact